MA50800A - Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson - Google Patents

Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Info

Publication number
MA50800A
MA50800A MA050800A MA50800A MA50800A MA 50800 A MA50800 A MA 50800A MA 050800 A MA050800 A MA 050800A MA 50800 A MA50800 A MA 50800A MA 50800 A MA50800 A MA 50800A
Authority
MA
Morocco
Prior art keywords
catecholamine
parkinson
disease
treatment
new
Prior art date
Application number
MA050800A
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Martin Juhl
Lisbet Kværnø
Jørgensen Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA50800A publication Critical patent/MA50800A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
MA050800A 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson MA50800A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24

Publications (1)

Publication Number Publication Date
MA50800A true MA50800A (fr) 2020-09-30

Family

ID=64661284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050800A MA50800A (fr) 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Country Status (25)

Country Link
US (3) US10729710B2 (fr)
EP (1) EP3713933A1 (fr)
JP (4) JP7320507B2 (fr)
KR (1) KR20200092955A (fr)
CN (3) CN117653649A (fr)
AR (1) AR113908A1 (fr)
AU (2) AU2018371193B2 (fr)
BR (1) BR112019014981A2 (fr)
CA (1) CA3082757A1 (fr)
CL (1) CL2020001343A1 (fr)
CO (1) CO2020006224A2 (fr)
CR (1) CR20200225A (fr)
EA (1) EA202090987A8 (fr)
EC (1) ECSP20030074A (fr)
GE (1) GEP20227446B (fr)
IL (1) IL274648A (fr)
JO (1) JOP20200114A1 (fr)
MA (1) MA50800A (fr)
MX (2) MX2020005366A (fr)
PE (1) PE20211290A1 (fr)
PH (1) PH12020550631A1 (fr)
SG (1) SG11202004461YA (fr)
TW (1) TWI816716B (fr)
UA (1) UA127575C2 (fr)
WO (1) WO2019101917A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50800A (fr) * 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP2022533311A (ja) 2019-05-21 2022-07-22 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US20220220077A1 (en) * 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113727979A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023208865A1 (fr) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab Nouveaux composés de 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations
WO2023208867A1 (fr) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab Nouveaux composés de 1,2,3,4,4a,5,8,9,10,10a-décahydrobenzo[g]quinolin-6(7h)-one et leurs utilisations
WO2023208869A1 (fr) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab Nouveaux esters de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations
WO2023242355A1 (fr) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Promédicaments d'apomorphine et leurs utilisations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
EP0077754B1 (fr) 1981-10-16 1990-09-26 Sandoz Ag Dérivés de 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline avec activité pharmaceutique
PH22782A (en) 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
EP0393781B1 (fr) 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine, précurseur de médicament
WO1990012574A1 (fr) 1989-04-25 1990-11-01 Northeastern University Composes agonistes de la dopamine
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
MXPA03001272A (es) 2000-08-11 2004-04-02 Purdue Research Foundation Procedimiento para la preparacion de dinapsolina.
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
JP2005504758A (ja) 2001-08-10 2005-02-17 パーデュー・リサーチ・ファウンデーション キラル・ジナプソリン
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
WO2003080074A1 (fr) 2002-03-19 2003-10-02 Michael Holick Derives de glycoside et de glycoside orthoester d'apomorphine, d'analogues et utilisations correspondantes
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
AU2004308413A1 (en) 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
WO2006012640A2 (fr) 2004-07-21 2006-02-02 Darpharma, Inc. Procedes d'administration d'agonistes du recepteur de la dopamine
WO2006056604A1 (fr) 2004-11-25 2006-06-01 Evolva Ag Derives de levodopa glycosyl, procedes de preparation et d'utilisation associes
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
EP2557079A1 (fr) 2011-08-09 2013-02-13 Nestec S.A. Synthèse de catéchine et conjugués d'épicatéchine
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
SI3209302T1 (sl) 2014-10-21 2019-06-28 Abb Vie Inc. Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
WO2017184871A1 (fr) 2016-04-20 2017-10-26 Abbvie Inc. Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727979A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727712A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
US20220220077A1 (en) 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2022533311A (ja) 2019-05-21 2022-07-22 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP2023013012A (ja) * 2021-07-15 2023-01-26 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
CA3082757A1 (fr) 2019-05-31
EA202090987A8 (ru) 2020-09-29
BR112019014981A2 (pt) 2020-04-07
US20220257623A1 (en) 2022-08-18
JP7443606B2 (ja) 2024-03-05
JP2023055830A (ja) 2023-04-18
CO2020006224A2 (es) 2020-05-29
US20200338102A1 (en) 2020-10-29
PH12020550631A1 (en) 2021-02-22
CN117599073A (zh) 2024-02-27
PE20211290A1 (es) 2021-07-20
US11110110B2 (en) 2021-09-07
TWI816716B (zh) 2023-10-01
JP2023145580A (ja) 2023-10-11
UA127575C2 (uk) 2023-10-18
CN111386267A (zh) 2020-07-07
JP7320507B2 (ja) 2023-08-03
CN117653649A (zh) 2024-03-08
TW201924693A (zh) 2019-07-01
EP3713933A1 (fr) 2020-09-30
RU2020116419A (ru) 2021-12-27
CR20200225A (es) 2020-07-25
MX2022016276A (es) 2023-02-09
US11707476B2 (en) 2023-07-25
WO2019101917A1 (fr) 2019-05-31
GEP20227446B (en) 2022-12-12
JP7320684B2 (ja) 2023-08-03
SG11202004461YA (en) 2020-06-29
AR113908A1 (es) 2020-06-24
KR20200092955A (ko) 2020-08-04
EA202090987A1 (ru) 2020-08-07
ECSP20030074A (es) 2020-07-31
US10729710B2 (en) 2020-08-04
CL2020001343A1 (es) 2020-09-25
IL274648A (en) 2020-06-30
AU2018371193A1 (en) 2020-06-11
CN111386267B (zh) 2023-12-12
JOP20200114A1 (ar) 2020-05-17
JP2021504345A (ja) 2021-02-15
US20190160083A1 (en) 2019-05-30
AU2018371193B2 (en) 2022-12-22
JP2023145579A (ja) 2023-10-11
MX2020005366A (es) 2020-08-13
AU2023201741A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3555629A4 (fr) Utilisation de gènes à médiation par motif apoe4 pour le diagnostic et le traitement de la maladie d'alzheimer
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA44681A (fr) Administration de b-sarcoglycane et de microarn-29 à l'aide d'un vecteur de virus adéno-associé, et traitement de la dystrophie musculaire
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
MA43861A (fr) Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
MA45719A (fr) Dérivé d'oxazine pour utilisation dans la prévention de la maladie d'alzheimer chez des patients à risque
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci